Prostate cancer decisions — 2025

The Board denied the Veteran's claim for an effective date prior to December 20, 2022, for a 100 percent evaluation of prostate cancer (status post radical prostatectomy).

The Board denied service connection for coronary artery disease, prostate cancer, and hypothyroidism prior to August 10, 2022.

The Board remands the claim for service connection for prostate cancer residuals to verify toxic environmental exposure and schedule an adequate VA examination.

The Board denied service connection for prostate cancer, ED, and a mental condition as they were not causally or etiologically related to the Veteran's active service.

The Board granted service connection for prostate cancer, to include as due to in-service exposure to herbicide agents, resolving all reasonable doubt in the Veteran's favor.

The Board granted service connection for prostate cancer and kidney cancer under the PACT Act, but remanded claims for erectile dysfunction, prostate cancer on a basis other than the PACT Act, and kidney cancer on a basis other than the PACT Act.

The Board remands the claims for service connection for prostate cancer and obstructive sleep apnea to schedule VA examinations and obtain medical opinions regarding their etiology, considering toxic exposure during service.

The Board granted an effective date of January 15, 2021, for service connection for prostate cancer and related conditions.

The Board denied service connection for prostate cancer residuals and lung cancer residuals as the evidence did not show a relationship to active military service.

The Board remands the service-connection claim for prostate cancer for further development, including a VA examination to address the Veteran's claims of direct and presumptive service connection based on exposure to contaminated water at Camp LeJeune.

The Board granted an initial rating of 100 percent for prostate cancer from November 1, 2023, to May 21, 2024, and denied an earlier effective date for the grant of service connection for prostate cancer. The claim for service connection for dementia was remanded.

The Board granted eligibility for the direct payment of attorney fees based on 20 percent of past due benefits awarded in a May 2023 rating decision, but denied entitlement to additional fees.

The Board denied service connection for diabetes mellitus type II, hypertension, and hypothyroidism prior to August 10, 2022, but granted a 10 percent rating for painful scars of the bilateral knees.

The Board denied an initial compensable disability rating for bilateral hearing loss and remanded the service connection claims for prostate cancer, kidney cancer, cervical spine disability, thoracolumbar spine disability, right hip disability, and left hip disability.

The Board denied service connection for prostate cancer as the evidence did not support a finding that it was incurred in or caused by active service, to include exposure to herbicides and diesel/jet fuels.

The Board remands the claim for service connection for metastatic prostate cancer with nocturia due to insufficient evidence regarding exposure to toxic materials, including ionizing radiation.

The Board restored the 100 percent rating for prostate cancer from August 1, 2022 to November 28, 2022 and denied a compensable rating for hypothyroidism. The effective date for TDIU was dismissed as moot.

The Board remands the claims for an initial compensable evaluation for erectile dysfunction and an increased initial evaluation for prostate cancer with proctectomy due to a duty to assist error regarding missing VA treatment records.

The Board denied earlier effective dates for service connection for Parkinson's disease, cerebral infarction, atrial fibrillation, prostate cancer, and obstructive sleep apnea.

The Board denied the Veteran's claim for service connection for prostate cancer, finding that there was no evidence of an in-service injury or event and that his prostate cancer did not have its onset during service.